Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma:Experimental and clinical scenarios  

作　　者：Swati Katoch Vinesh Sharma Vikram Patial 

机构地区：[1]Division of Dietetics and Nutrition Technology,Institute of Himalayan Bioresource Technology,Palampur 176061,Himachal Pradesh,India [2]Academy of Scientific and Innovative Research,Ghaziabad 201002,UP,India

出　　处：《World Journal of Gastroenterology》2022年第28期3535-3554,共20页世界胃肠病学杂志（英文版）

基　　金：CSIR,India,No.MLP0204

摘　　要：Hepatocellular carcinoma(HCC)is the most common type of liver cancer worldwide.Viral hepatitis is a significant risk factor for HCC,although metabolic syndrome and diabetes are more frequently associated with the HCC.With increasing prevalence,there is expected to be>1 million cases annually by 2025.Therefore,there is an urgent need to establish potential therapeutic targets to cure this disease.Peroxisome-proliferator-activated receptor gamma(PPARγ)is a ligand-activated transcription factor that plays a crucial role in the pathophysiology of HCC.Many synthetic agonists of PPARγsuppress HCC in experimental studies and clinical trials.These synthetic agonists have shown promising results by inducing cell cycle arrest and apoptosis in HCC cells and preventing the invasion and metastasis of HCC.However,some synthetic agonists also pose severe side effects in addition to their therapeutic efficacy.Thus natural PPARγagonists can be an alternative to exploit this potential target for HCC treatment.In this review,the regulatory role of PPARγin the pathogenesis of HCC is elucidated.Furthermore,the experimental and clinical scenario of both synthetic and natural PPARγagonists against HCC is discussed.Most of the available literature advocates PPARγas a potential therapeutic target for the treatment of HCC.

关 键 词：ANTICANCER Hepatocellular carcinoma Natural agonists Peroxisome proliferator-activated receptor-γ THIAZOLIDINEDIONES 

分 类 号：R735.7[医药卫生—肿瘤]